Developed by the Clinton Health Access Initiative (CHAI) for its country teams and ministries of health, this tool can be used to assess the financial benefits of integrating tuberculosis (TB), HIV, and HCV testing on the GeneXpert machine. The tool only covers cross-cutting costs (i.e. not disease-specific) regarding the use of GeneXpert, such as equipment, service and maintenance, connectivity and human resources. This tool assumes that integration of testing will lead to significant savings around these cross-cutting costs. It should be set up taking into account country-specific testing targets across programs and operational assumptions.